Long-term outcomes in patients with BRAF V600 Long-term outcomes in patients with BRAF V600- mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy_ Analysis from phase 2 and 3 clinical trials RETOUR MarcGuevreguian2021-03-22T20:25:49+01:00
